CHINA – ONE OF THE FASTEST GROWING COUNTRIES FOR BIOPHARMA

Accelerating medical innovation has become china's national strategy

China government has successively released supportive policies to encourage the development of pharmaceutical R&D improving patient access/affordability and healthcare service efficiency.

IND[1] process	Number of IND processed cases	NDA[3] process	CN & US launch time lag
27 mos. (2015 AVG) › 3 mos. (After new policy issued)	4,944 (2014) › 12,068 (2016)	26 mos. (2015 AVG) › ~10 mos. (After new policy issued)	5-7 yrs. (Before 2015) › In Sync. (After NMPA reform)
IND 60-day acquiescence, OHGRA[2] filing simplification	Pre-IND meeting simplification, GCP record-based system reform	Priority review, special review and conditional approval procedure	Acceptance of the overseas clinical trial data

Note: 1. IND = Investigational New Drug (also known as CTA = Clinical Trial Application), 2. OHGRA: Office of Human Genetic Resource Administration, 3. NDA: New Drugs Application
Source: Government official website, IQVIA analysis

IQVIA BIOTECH CHINA

IQVIA – Your trusted partner for EBP clinical trial development and market entry

We offer a comprehensive set of flexible solutions that can be customized to your specific needs, meeting you where you are in the development journey.

Resource advantage



70%/30% - Oncology/Non-Oncology experience

50% - Experienced CRA > **4 years**

24% - Decentralized staff in 18 cities

4 years in average-project management experience

Board capacity from china only to regional and global

Abundant experience

>60 Studies

>870 Sites initiated

>7050 Patients randomized

Key therapeutic areas

Oncology	Hematology
Ophthalmology	Infectious disease
Cardiovascular	Dermatology
Neurology	Endocrinology

- Branding & commercial strategy
- Commercial intelligence
- Pricing & market access
- Strategy & portfolio analysis
- Commercial effectiveness services

IQVIA BIOTECH

At IQVIA Biotech, we are using unparalleled real-world data and advanced technologies to dramatically improve clinical trial performance, and therapeutic and operational expertise to bring clarity and predictability to the design and start-up processes.

IQVIA Biotech's five key solution areas

Advance asset value across key activities and milestones



IQVIA Biotech's five key solution areas support you at different milestones in your journey. our suite of flexible solutions enables you to pick and choose what's right for you. no matter where you are in your development or commercialization journey, IQVIA Biotech can help you advance your asset with confidence and credibility.

IQVIA extensive therapeutic expertise and experience

>475 oncology studies

>125 hematology/oncology

>95 immuno-oncology

~125 dermatology studies

>300 CNS studies

~130 immunology studies

>100 cardiovascular studies

Early Phase Oncology Network (EPON)

Established network of qualified Phase I oncology sites work in close alignment to achieve goals, mitigate risk, and increase efficiency.

Early Phase Organizations with:

High performance and high quality deep collaborative relationships:

Experienced people & processes
Joint-accountability/efficiency goals
Operational alignment goals
Lessons learned applied

Hundreds with established, actively managed IQVIA relationships

700+ sites in 60+ countries

IQVIA BIOTECH

CONTACT US

9/F.,Office Tower 3, Sun Dong An Plaza,
138 Wangfujing Ave. Dongcheng Dist., Beijing, China
qun.liu@quintiles.com
iqvia.com